The New Eugenics: The Case Against Genetically Modified Humans
By Marcy Darnovsky,
Different Takes (Spring 2000)
| 11. 30. 1999
Published by the Hampshire College Population and Development Program
At the cusp of dot-com frenzy and the biotech century, a group of influential scientists and pundits has begun zealously promoting a new bio-engineered utopia. In the world of their visionary fervor, parents will strive to afford the latest genetic "improvements" for their children. According to the advocates of this human future (or, as some term it, "post-human" future), the exercise of consumer preferences for offspring options will be the prelude to a grand achievement: the technological control of human evolution.
My first close encounter with this techno-eugenic enthusiasm was in a 1997 book written for an unconverted lay audience by Princeton geneticist Lee M. Silver. In Remaking Eden: Cloning and Beyond in a Brave New World (New York: Avon Books 1998), Silver spins out scenarios of a future in which affluent parents are as likely to arrange genetic enhancements for their children as to send them to private school.
Silver confidently predicts that upscale baby-making will soon take place in fertility clinics, where prospective parents will undergo an IVF procedure...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...